Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Department of Pathology, The First Hospital of Jilin University, Changchun, Jilin, China.
Front Immunol. 2024 Oct 23;15:1486214. doi: 10.3389/fimmu.2024.1486214. eCollection 2024.
Lung enteric-type adenocarcinoma (ETAC) is a rare subtype of non-small cell lung cancer (NSCLC), comprising approximately 0.6% of all primary lung adenocarcinomas. It is characterized by a tendency for early metastasis and a prognosis comparable to that of common lung adenocarcinoma. This case report described a patient with lung-ETAC who developed gastric metastasis. The patient underwent treatment with chemotherapy and a PD-1 inhibitor, resulting in disease remission with a progression-free survival (PFS) of 8 months. The follow-up time was 13 months. This case report was aimed to enhance understanding of the biological behavior of this rare tumor and provide insights into potential future treatment strategies.
肺肠型腺癌（ETAC）是一种罕见的非小细胞肺癌（NSCLC）亚型，约占所有原发性肺腺癌的 0.6%。它的特点是早期转移倾向和预后与常见的肺腺癌相当。本病例报告描述了一例肺 ETAC 患者发生胃转移。该患者接受了化疗和 PD-1 抑制剂治疗，疾病缓解，无进展生存期（PFS）为 8 个月。随访时间为 13 个月。本病例报告旨在增强对这种罕见肿瘤的生物学行为的理解，并为潜在的未来治疗策略提供思路。
